Promise Bio

Promise Bio, a recent spin-out from the Weizmann Institute, is the first company to harness post-translational modifications (PTM) and artificial intelligence to reveal unique biological insights that are otherwise overlooked. Understanding immune-mediated diseases requires uncovering intricate proteomic patterns, and PTMs are the key to capturing the regulated part of the proteome. The PROMISE platform uses proprietary Comprehensive PTM Profiling to detect up to 45 PTM types simultaneously, allowing maximal knowledge extraction from biological data and offering a unique approach to identifying functional biomarkers from diverse biological samples (PBMCs, tissue biopsies, urine). With a proprietary technology recently published in Nature Biotechnology, we partner with pharmaceutical companies to unleash the potential of their data-driven discovery, by looking at biology where it matters the most for complex chronic diseases.

Promise Bio has raised $9M in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include Awz Ventures, AION Labs.

Promise Bio was founded in 2023 by Ronel Veksler (Co-founder & CEO).

Promise Bio operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Artificial Intelligence, Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Promise Bio is based in Tel Aviv-Yafo, Israel.